Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports

Lim, Sung-Shick; Gillis, David; Smith, William B.; Hissaria, Pravin; Greville, Hugh; Peh, Chen Au

doi:10.1111/j.1445-5994.2006.01055.x

Cited by 46 publications

(19 citation statements)

References 13 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although there are no published trials on the use of rituximab for RA-ILD, Popa et al found that RA patients treated with rituximab for 7 years have not shown any evidence of new RA-ILD [97]. There are also several cases reporting the successful use of weekly rituximab for ILD in other forms of collagen vascular disease [98–101]. …”

Section: Other Possible Drug Therapiesmentioning

confidence: 99%

Rheumatoid Arthritis-Associated Interstitial Lung Disease: Diagnostic Dilemma

Hamblin

Horton

2011

Pulmonary Medicine

View full text Add to dashboard Cite

Interstitial lung disease (ILD) is an increasingly recognized complication of rheumatoid arthritis (RA) contributing to significantly increased morbidity and mortality. Diagnosis can be challenging since patients are unlikely to report dyspnea due to an overall decrease in physical activity with advanced arthritic symptoms. Additionally, infections, drug toxicity, and environmental toxins can mimic ILD, creating significant diagnostic dilemmas for the clinician. In this paper we will explore an effective clinical algorithm for the diagnosis of RA-ILD. We will also discuss features of drug-related toxicities, infections, and environmental toxins that comprise the main entities in the differential diagnosis of RA-ILD. Finally, we will explore the known and experimental treatment options that may have some benefit in the treatment of RA-ILD.

show abstract

Section: Other Possible Drug Therapiesmentioning

confidence: 99%

Rheumatoid Arthritis-Associated Interstitial Lung Disease: Diagnostic Dilemma

Hamblin

Horton

2011

Pulmonary Medicine

View full text Add to dashboard Cite

show abstract

“…Although data in SLE patients are limited, steroid sparing agents like cyclophosphamide, azathioprine, mycophenolate, rituximab have been used in the past. [11] …”

Section: Discussionmentioning

confidence: 99%

Interstitial Lung Disease in Systemic Lupus Erythematosis: A case report

Malhotra¹,

Chandrakar²,

Shetty³

2017

AIMDR

View full text Add to dashboard Cite

Introduction: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease of unknown etiology that can affect virtually every organ in the body. Presentation of a patient can vary considerabaly. Many a times, pleurisy, coughing, and/or dyspnea are the first clues either to lung involvement or to SLE itself. In this case report we present a patient who was diagnosised with SLE along with pulmonary diagnosis of interstitial lung diasese (ILD). Case report: A 40 year old female presented with swelling of both lower extremities, facial puffiness for one month and dry cough for past 3 years. Examination revealed painful joints and bilateral fine crepts at the bases of lungs. Patient's ANA and anti-double stranded DNA indicated SLE. Pulmonary function test showed restrictive pattern of lung disease compatible with interstitial lung disease (ILD), which was supported by High resolution computed tomography thorax. 2D echocardiography revealed mild tricuspid rgurgitation and pulmonary artery systolic pressure of 80 mm of mercury. Based on the clinical and laboratory findings present in this patient, a final diagnosis of SLE with ILD and pulmonary hypertension was made. Treatment included immunosuppresive therapy, mycophenolate mofetil, pirfenidone and sildenafil. Mild improvement of respiratory symptoms was noted in the patient. Conclusion: Careful history taking, clinical examination and appropriate clinical investigations helped us in clinching the diagnosis. Further research is required to understand the mechanisms responsible for ILD in SLE patients and how these cases can be treated effectively.

show abstract

“…If there is no prompt improvement, then intravenous methylprednisolone with an immunosuppressive agent such as cyclophosphamide is commonly used. One report described a patient with acute lupus pneumonitis who responded to weekly rituximab with a rapid improvement in subjective symptoms and pulmonary function test abnormalities [84]. …”

Section: Other Connective Tissue Disease-associated Interstitial Lungmentioning

confidence: 99%

Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management

2010

View full text Add to dashboard Cite

Interstitial lung disease (ILD) is a challenging clinical entity associated with multiple connective tissue diseases, and is a significant cause of morbidity and mortality. Effective therapies for connective tissue disease-associated interstitial lung disease (CTD-ILD) are still lacking. Multidisciplinary clinics dedicated to the early diagnosis and improved management of patients with CTD-ILD are now being established. There is rapid progress in understanding and identifying the effector cells, the proinflammatory and profibrotic mediators, and the pathways involved in the pathogenesis of CTD-ILD. Serum biomarkers may provide new insights as risk factors for pulmonary fibrosis and as measures of disease progression. Despite these recent advances, the management of patients with CTD-ILD remains suboptimal. Further studies are therefore urgently needed to better understand these conditions, and to develop effective therapeutic interventions.

show abstract

Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports

Cited by 46 publications

References 13 publications

Rheumatoid Arthritis-Associated Interstitial Lung Disease: Diagnostic Dilemma

Rheumatoid Arthritis-Associated Interstitial Lung Disease: Diagnostic Dilemma

Interstitial Lung Disease in Systemic Lupus Erythematosis: A case report

Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management

Contact Info

Product

Resources

About